Component

Allicin-containing supplement in Josling 2001

Allicin-containing supplement in Josling 2001. Interpret through the linked study species, preparation, exposure and measured endpoint.

2 recorded relationships. Experimental role, claim status and evidence remain attached to each record.

How nutrients influence it

Every nutrient with a recorded effect on this component, credited to the nutrient that acted rather than the chapter that recorded it. Open a nutrient to see the findings and the conditions they were measured under.

How nutrients reach it in more than one step

Chains of two or more recorded steps that end here, grouped by the nutrient they start from. Each step is a separate finding, so a chain is a route a mechanism could take, not proof that it does.

Tracing routes…

What it does

Every recorded relationship this component is part of, grouped by its role. Plain wording comes first; the technical statement follows.

Recorded relationships

What it acts on

  1. The allicin-containing supplement trial recorded 24 cold episodes versus 65 with placebo.

    Experimental context and source evidence
    evidence_access
    Primary indexed abstract reviewed; full methods, exact concentrations or species-specific attribution remain unextracted unless explicitly stated in the abstract or separately verified publisher text.
    experimental_contrast
    {"intervention": "Tested allicin-containing supplement", "comparator": "Placebo", "endpoint": "The allicin-containing supplement trial recorded 24 cold episodes versus 65 with placebo.", "effect_direction": "decrease", "combination": "single", "conditions": []} Explicit extracted experimental comparison; source-derived draft.
    experimental_model
    146 volunteers randomized, one capsule/day for 12 weeks; self-reported diaries.
    interpretation_status
    Source-derived extraction of a fact-checked reference; access is explicit, not independent raw-data verification.
    limitations
    Episodes are not numbers of infected participants; not pure allicin target engagement or proof of mechanism.
    plain_language
    The allicin-containing supplement trial recorded 24 cold episodes versus 65 with placebo.
    primary_references
    Preventing the common cold with a garlic supplement: a double-blind, placebo-controlled survey. | 2001 | DOI 10.1007/bf02850113 | PMID 11697022 | https://pubmed.ncbi.nlm.nih.gov/11697022/ | https://doi.org/10.1007/bf02850113
    source_locator
    Reviewed reference lines 95-95; exact primary location described in quoted passage where extracted.

    Allicin: detailed mechanisms of action (reviewed 5 October 2026) · lines 95–95

    Original AI-assisted review of primary studies and, where relevant, official regulatory records. Access level is retained per claim. Corrections, null results and unresolved questions remain explicit. Not publisher full text or independent replication. · supports · 146 volunteers randomized, one capsule/day for 12 weeks; self-reported diaries. · source_derived_draft · unverified_draft

    **Cold outcomes differ by preparation.** Josling's trial randomized 146 volunteers for twelve weeks and reported fewer diary-recorded colds with an allicin-containing supplement (24 versus 65 episodes). Nantz tested 2.56 g/day aged garlic extract in 120 participants: the ninety-day cold/flu incidence difference was not significant, although some symptom and activity-impact measures improved. At forty-five days, ex vivo γδ-T-cell and NK-cell proliferation also increased. These are different interventions and endpoints, not a replication of purified allicin efficacy. Neither proves that one specific compound caused the clinical effect. [Josling 2001](https://pubmed.ncbi.nlm.nih.gov/11697022/) [Nantz 2012](https://pubmed.ncbi.nlm.nih.gov/22280901/)
    Complete structured claim and evidence

What acts on it

  1. The garlic-supplement-josling-2001 study is a preparation-specific translation comparison; its outcomes are not assigned to purified allicin.

    Experimental context and source evidence
    evidence_access
    Primary indexed abstract reviewed; full methods, exact concentrations or species-specific attribution remain unextracted unless explicitly stated in the abstract or separately verified publisher text.
    experimental_model
    Editorial study-scope relationship, not experimental causation or chemical composition.
    interpretation_status
    Source-derived extraction of a fact-checked reference; access is explicit, not independent raw-data verification.
    limitations
    Unsigned navigation only. Does not assert allicin content, metabolic conversion, causation or intervention equivalence.
    plain_language
    The garlic-supplement-josling-2001 study is a preparation-specific translation comparison; its outcomes are not assigned to purified allicin.
    primary_references
    Preventing the common cold with a garlic supplement: a double-blind, placebo-controlled survey. | 2001 | DOI 10.1007/bf02850113 | PMID 11697022 | https://pubmed.ncbi.nlm.nih.gov/11697022/ | https://doi.org/10.1007/bf02850113
    source_locator
    Reviewed reference lines 95-95; exact primary location described in quoted passage where extracted.

    Allicin: detailed mechanisms of action (reviewed 5 October 2026) · lines 95–95

    Original AI-assisted review of primary studies and, where relevant, official regulatory records. Access level is retained per claim. Corrections, null results and unresolved questions remain explicit. Not publisher full text or independent replication. · supports · Editorial study-scope relationship, not experimental causation or chemical composition. · source_derived_draft · unverified_draft

    **Cold outcomes differ by preparation.** Josling's trial randomized 146 volunteers for twelve weeks and reported fewer diary-recorded colds with an allicin-containing supplement (24 versus 65 episodes). Nantz tested 2.56 g/day aged garlic extract in 120 participants: the ninety-day cold/flu incidence difference was not significant, although some symptom and activity-impact measures improved. At forty-five days, ex vivo γδ-T-cell and NK-cell proliferation also increased. These are different interventions and endpoints, not a replication of purified allicin efficacy. Neither proves that one specific compound caused the clinical effect. [Josling 2001](https://pubmed.ncbi.nlm.nih.gov/11697022/) [Nantz 2012](https://pubmed.ncbi.nlm.nih.gov/22280901/)
    Complete structured claim and evidence

In the sources

Preserved passages that mention this component, quoted exactly. Open one to read it in context.

    This is a research prototype built from draft material. It is not medical advice, and its statements still await verification against the original studies.